Check cytokine filtration for people getting double lung transplants
Part of Immune system & allergy, Lungs & breathing clinical trials.
This study tests a method during double lung transplant surgery to remove certain immune signals (“cytokines”) that may help the transplanted lungs heal. It’s only for adults who are having a planned double lung transplant at the study sites.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be scheduled and able to receive a double lung transplant at one of the study hospitals
- You must be age 18 or older
- You cannot have had any prior organ transplant
- At the time of surgery, you must not need medicines that suppress the immune system (immunosuppressants)
- You must not have had certain immune-related antibody treatments in the week before surgery
- You must be willing to take part (consent)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at ways to improve outcomes for people who are waiting for or have recently received a lung transplant. It aims to find better management strategies for both donors and recipients.
This study looks for lab “clues” that can help predict how well someone’s lungs will do after a lung transplant. It may help doctors spot transplant-related problems earlier so care can be planned sooner.
This Phase 2 study monitors how your immune system reacts to CMV (a common virus) after a lung transplant. It may help doctors understand which patients are better protected and could guide future treatments to reduce CMV-related complications.
This study follows people who are getting a double lung transplant and have specific lung-only (or lung-limited) cancer or other serious lung conditions. It’s an observational registry, meaning it collects real-world information to learn which patients may benefit from transplant and how they do afterward.
This trial tests a drug called tocilizumab (brand name Actemra) to see if it helps prevent rejection after lung transplantation. Tocilizumab targets part of the immune system that may otherwise attack the new lungs.
This study tests whether a blood-filter treatment used during a heart transplant can improve how the transplant goes for adults. You might be eligible if you’re having a heart transplant and meet the specific medication and procedure requirements.
Hear when a new Lung Transplant Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.